{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:23:28Z","timestamp":1788985408445,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, represents a novel approach to systemic psoriasis treatment, offering the advantages of oral administration and selective inhibition of cytokine signaling pathways involved in psoriasis pathogenesis. This review evaluates the efficacy and safety of deucravacitinib based on findings from phase III clinical trials, including POETYK PSO\u20101, PSO\u20102, PSO\u20104, and long\u2010term extension studies. In these trials, deucravacitinib demonstrated superior efficacy compared to placebo and apremilast, with a significantly higher proportion of patients achieving \u2265\u200975% improvement in Psoriasis Area and Severity Index (PASI 75). Long\u2010term data suggest sustained efficacy through 3\u2009years of continuous treatment. Deucravacitinib was well tolerated, with a safety profile characterized by low rates of serious adverse events, including infections and major cardiovascular events. The most common adverse events included nasopharyngitis, upper respiratory tract infections, and acne, with herpes zoster occurring at a low incidence. The results of the phase III trials support deucravacitinib as an effective oral alternative to biologic therapies, with sustained efficacy and a favorable safety profile. Future studies should explore head\u2010to\u2010head comparisons with interleukin (IL)\u201017 and IL\u201023 inhibitors to define their role in psoriasis management better.<\/jats:p>","DOI":"10.1111\/ijd.70023","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:10:12Z","timestamp":1755749412000},"page":"238-244","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Review of Phase\n                    <scp>III<\/scp>\n                    and Long\u2010Term Data for Deucravacitinib for Plaque Psoriasis"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4393-9511","authenticated-orcid":false,"given":"Nickoulet","family":"Babaei","sequence":"first","affiliation":[{"name":"Loma Linda University School of Medicine  Loma Linda California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Loma Linda University School of Medicine  Loma Linda California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9058-7160","authenticated-orcid":false,"given":"Mireya","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Albany Medical College  Albany New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seanna","family":"Yang","sequence":"additional","affiliation":[{"name":"Tulane University School of Medicine  New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minka","family":"Gill","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-1892","authenticated-orcid":false,"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Miller School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1395800"},{"key":"e_1_2_7_3_1","first-page":"139","article-title":"Comorbidity in Adult Psoriasis: Considerations for the Clinician","volume":"12","author":"Daugaard C.","year":"2022","journal-title":"Psoriasis (Auckland)"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1391"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-012-8307-1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707449"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622318759282"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00878-9"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34293-y"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2013.02.003"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061506"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"e_1_2_7_17_1","volume-title":"Sotyktu [Package Insert]","year":"2022"},{"key":"e_1_2_7_18_1","volume-title":"Sotyktu Japan [Package Insert]","year":"2022"},{"key":"e_1_2_7_19_1","volume-title":"Sotyktu [Product Monograph]","year":"2022"},{"key":"e_1_2_7_20_1","volume-title":"Sotyktu [Product Information]","year":"2022"},{"key":"e_1_2_7_21_1","volume-title":"Sotyktu [Summary of Product Characteristics]","year":"2023"},{"key":"e_1_2_7_22_1","volume-title":"Sotyktu [Package Insert]","year":"2023"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae014"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4688"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17074"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.70023","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:23:31Z","timestamp":1770726211000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.70023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/ijd.70023"],"URL":"https:\/\/doi.org\/10.1111\/ijd.70023","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"2025-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}